On Assignment, Inc. (NASDAQ: ASGN) — 2011 Form 10-K
Entity and period: The filing is for On Assignment, Inc., not Everforth Inc. It reports the fiscal year ended December 31, 2011; it is an annual report, not a standalone fourth-quarter filing. Unless otherwise noted, figures below are in U.S. dollars.
Business context
On Assignment provides contract, contract-to-hire, and direct-hire staffing in Life Sciences, Healthcare, Physician, and IT and Engineering. IT and Engineering was the largest segment, contributing 44.7% of 2011 revenue. The company acquired Valesta in February and HealthCare Partners in July 2011; Cambridge and Sharpstream had been acquired in 2010.
Financial results and liquidity
- Revenue: $597.3 million, up 36.3% from $438.1 million in 2010. All four segments grew; acquisitions contributed $48.1 million of 2011 revenue.
- Profitability: Gross profit was $200.1 million, up from $149.5 million; gross margin declined to 33.5% from 34.1%. Operating income was $44.4 million versus $3.2 million, and net income was $24.3 million versus a $9.9 million net loss. Diluted EPS was $0.64 versus a loss of $0.27 per share.
- Costs and margins: SG&A rose 19.0% to $155.7 million, while SG&A as a share of revenue improved to 26.1% from 29.9%. The 2010 comparison included a $15.4 million Nurse Travel goodwill impairment charge.
- Cash flow: Operating cash flow was $23.4 million, down from $26.9 million. Investing used $41.1 million, including $32.8 million for acquisitions and $8.4 million for capital expenditures. Cash declined by $0.7 million to $17.7 million.
- Liquidity and debt: Working capital was $74.7 million. Total debt was $86.8 million, up from $66.8 million; the filing reports $81.8 million as long-term debt and $5.0 million as current. The company reported compliance with credit-facility covenants at year-end and said liquidity, its credit facility, and expected operating cash flow should cover obligations and needs for the next 12 months.
- Other balance-sheet items: Total assets were $410.7 million and stockholders’ equity was $246.7 million. Goodwill was $229.2 million; the 2011 annual impairment test found no impairment.
Segment performance and changes
- Life Sciences: Revenue $155.3 million, up 41.9%; growth reflected more professionals on assignment, higher average bill rates, and acquisitions.
- Healthcare: Revenue $94.6 million, up 24.0%; management cited improved demand, but the segment remained soft. Gross margin fell to 28.2% from 30.2%.
- Physician: Revenue $80.6 million, up 9.5%, including acquired-business contributions. The legacy business declined; average bill rate fell 1.9%.
- IT and Engineering: Revenue $266.7 million, up 49.3%, supported by higher assignment volume and bill rates. Gross margin decreased to 35.6% from 36.3%.
- International revenue increased to $68.1 million, or 11.4% of total revenue, from $30.7 million, or 7.0%, in 2010.
Outlook, risks, and unusual items
- Management anticipated improving markets in 2012 and planned continued investment in existing businesses, permanent-placement capabilities, and possible acquisitions. It estimated 2012 capital expenditures of approximately $8 million. The filing does not provide a specific company revenue or earnings forecast.
- The company increased its sales and recruiting workforce; the average number of recruiters and sales personnel rose 23.0% during 2011. It also planned to continue its authorized share repurchase program; $15.8 million of authorization remained at year-end.
- Key risks include economic cyclicality and staffing demand, pricing competition, reliance on attracting and retaining qualified professionals and recruiters, at-will assignment terminations, healthcare reimbursement and regulatory changes, rising payroll, insurance, travel, and housing costs, and integration of acquisitions.
- Healthcare reform could increase coverage costs for temporary employees; management said it could not yet estimate the net impact and that it could be significant. Other notable exposures include partially self-insured workers’ compensation and malpractice claims, and approximately $10.2 million of potential acquisition earn-outs through 2013.
- Debt totaled $86.8 million, with $61.8 million identified as variable-rate exposure before the interest-rate swap; management estimated a 1 percentage point rate change would affect annual interest expense by about $0.6 million after the swap. The credit facility matures in December 2015 and includes financial covenants.
- Legal matters were described as arising in the ordinary course; management did not expect their disposition to materially affect the financial statements. Deloitte issued unqualified opinions on the financial statements and internal control over financial reporting; management also reported effective disclosure controls.
Important facts for investors to verify
- How much of revenue and earnings growth came from acquired businesses versus organic growth, especially in Life Sciences and IT and Engineering.
- Whether gross-margin pressure in Healthcare and IT and Engineering persists, and whether the Physician legacy business recovers.
- Cash conversion and receivables: net accounts receivable increased to $93.9 million from $62.5 million while operating cash flow declined.
- Debt repayment and covenant headroom, including the 2015 maturity and variable-rate exposure.
- Realization of acquisition earn-outs and integration benefits; the Valesta and HCP purchase-price allocations were preliminary.
- Potential costs from healthcare reform, self-insured claims, and the company’s substantial goodwill balance.